Study of Intraventricular Cerliponase Alfa for CLN2 Disease
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
Background Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children. Methods In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years. Treatment was initiated at a dose of 30 mg, 100 mg, or 300 mg; all the patients then received the 300-mg dose for at least 96 weeks. The primary outcome was the time until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale (which ranges from 0 to 6, with 0 representing no function and 3 representing normal function in each of the two domains), which was compared with the time until a 2-point decline in 42 historical controls. We also compared the rate of decline in the motor-language score between the two groups, using data from baseline to the last assessment with a score of more than 0, divided by the length of follow-up (in units of 48 weeks). Results Twenty-four patients were enrolled, 23 of whom constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Precision therapy using intracerebroventricular enzyme replacement with recombinant human tripeptidyl peptidase 1 slowed disease progression in one study 148 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [148]
Citations
Cites
Sleat, D. E., Donnelly, R. J., Lackland, H., Liu, C.-G., Sohar, I., Pullarkat, R. K., & Lobel, P. (1997) · Science · doi:10.1126/science.277.5333.1802 · Cited by 581
NCL diseases - clinical perspectives
Schulz, A., Kohlschütter, A., Mink, J., Simonati, A., & Williams, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.008 · Cited by 246
Self-citationSleat, D. E., Gin, R. M., Sohar, I., Wisniewski, K., Sklower-Brooks, S., Pullarkat, R. K., Palmer, D. N., Lerner, T. J., Boustany, R.-M., Uldall, P., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302427 · Cited by 178
Steinfeld, R., Heim, P., von Gregory, H., Meyer, K., Ullrich, K., Goebel, H. H., & Kohlschütter, A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10660 · Cited by 178
Self-citationThe Genetic Spectrum of Human Neuronal Ceroid‐lipofuscinoses
Mole, S. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00500.x · Cited by 115
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis
Worgall, S., Kekatpure, M. V., Heier, L., Ballon, D., Dyke, J. P., Shungu, D., Mao, X., Kosofsky, B., Kaplitt, M. G., Souweidane, M. M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267885.47092.40 · Cited by 112
Self-citationKatz, M. L., Coates, J. R., Sibigtroth, C. M., Taylor, J. D., Carpentier, M., Young, W. M., Wininger, F. A., Kennedy, D., Vuillemenot, B. R., & O'Neill, C. A. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23423 · Cited by 100
Kishnani, P. S., Dickson, P., Muldowney, L., Lee, J. J., Rosenberg, A. S., Abichandani, R., Bluestone, J. A., Burton, B. K., Dewey, M. C., Freitas, A., et al. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.11.001 · Cited by 95
Vuillemenot, B. R., Katz, M. L., Coates, J. R., Kennedy, D., Tiger, P. M. N., Kanazono, S., Lobel, P., Sohár, I., Xu, S., Cahayag, R., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.018 · Cited by 81
Vuillemenot, B. R., Kennedy, D., Cooper, J. D., Wong, A. M. S., Sri, S., Doeleman, T., Katz, M. L., Coates, J. R., Johnson, G. C., Reed, R. P., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.004 · Cited by 60
Research works printed but not linked: 1
- Mole SE, Williams RE, Goebe HH, eds. The neuronal ceroid lipofuscinoses (Batten disease). 2nd ed. Oxford, England: Oxford University Press, 2011.
Cited by
Items 101–200 of 498
CLN3, at the crossroads of endocytic trafficking
Cotman, S. L., & Lefrançois, S. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136117 · Cited by 32
Neurofilament light is a treatment‐responsive biomarker in CLN2 disease
Ru, Y., Corado, C. R., Soon, R. K., Melton, A. C., Harris, A., Yu, G. K., Pryer, N., Sinclair, J. R., Katz, M. L., Ajayi, T., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50942 · Cited by 33
“Details of the subject eligibility criteria have been published elsewhere.(5) A single pretreatment (i.”
BackgroundMethodInfluentialSelf-citationCardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity
Rietdorf, K., Coode, E., Schulz, A., Wibbeler, E., Bootman, M. D., & Østergaard, J. R. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165643 · Cited by 29
Self-citationReyes, E. D. L., Lehwald, L. M., Augustine, E. F., Berry‐Kravis, E., Butler, K., Cormier, N., Demarest, S., Lu, S., Madden, J., Olaya, J. E., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.018 · Cited by 32
Diagnostic and severity scores for Cockayne syndrome
Spitz, M., Séverac, F., Obringer, C., Baer, S., May, N. L., Calmels, N., & Laugel, V. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01686-8 · Cited by 34
“This scoring approach has been successfully used in ceroidlipofuscinosis [21, 22] and very similar approaches based on functional scores are now routinely used in gene therapies for spinal muscular atrophy or Duchenne muscular dystrophy [23–26].”
MethodNovel plasma protein biomarkers from critically ill sepsis patients
Nynatten, L. R. V., Slessarev, M., Martin, C. M., Leligdowicz, A., Miller, M. R., Patel, M. A., Daley, M., Patterson, E. K., Cepinskas, G., & Fraser, D. D. (2022) · Clinical Proteomics · doi:10.1186/s12014-022-09389-3 · Cited by 31
“The serine protease TPP1 regulates lysosomal proteins [62], as well as mitochondrial trafficking and cellular metabolism [63], suggesting a role in cellular metabolism [64].”
BackgroundA Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting With Movements Disorders
Ortigoza‐Escobar, J. D. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.582160 · Cited by 31
Targeting the Choroid Plexuses for Protein Drug Delivery
Bryniarski, M. A., Ren, T., Rizvi, A. R., Snyder, A. M., & Morris, M. E. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100963 · Cited by 29
Schaefers, J., van der Giessen, L. J., Klees, C., Jacobs, E. H., Sieverdink, S., Dremmen, M. H. G., Spoor, J. K. H., van der Ploeg, A. T., van den Hout, J. M. P., & Huidekoper, H. H. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01858-6 · Cited by 29
“CLN2 clinical rating scale The CLN2 Clinical Rating Scale (CLN2 CRS) [5, 15] (“Appendix”) was used as the primary outcome measure in order to compare results with those reported in the first patient trial with cerliponase alfa [15].”
BackgroundMethodResultInfluentialDiagnostic approach in adult-onset neurometabolic diseases
Fernández‐Eulate, G., Carreau, C., Benoist, J., Lamari, F., Rucheton, B., Shor, N., & Nadjar, Y. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328045 · Cited by 28
Li, Y., & Izem, R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5496 · Cited by 32
Sindelar, M., Dyke, J. P., Deeb, R. S., Sondhi, D., Kaminsky, S. M., Kosofsky, B. E., Ballon, D., Crystal, R. G., & Gross, S. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-33449-0 · Cited by 29
Self-citationDyke, J. P., Xu, H. S., Verma, A., Voss, H. U., & Chazen, J. L. (2020) · Clinical Imaging · doi:10.1016/j.clinimag.2020.04.043 · Cited by 37
Self-citationNeuronal Ceroid Lipofuscinosis—Concepts, Classification, and Avenues for Therapy
Zhang, Y., Du, B., Zou, M., Peng, B., & Rao, Y. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70261 · Cited by 36
“In 2017, human recombinant TPP1 (tripeptidyl peptidase 1; cerliponase alfa) was approved for the treatment of CLN2 through intracerebroventricular (ICV) injection of 300 mg every other week [11, 174, 175].”
Bridging the Gap Between RCTs and RWE Through Endpoint Selection
LoCasale, R. J., Pashos, C. L., Gutierrez, B., Dreyer, N. A., Collins, T., Calleja, A., Seewald, M. J., Plumb, J. M., Liwing, J., Tepie, M. F., et al. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00193-5 · Cited by 28
Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders
Limia, C. E. G., Baird, M., Schwartz, M., Saxena, S., Meyer, K., & Wein, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12121979 · Cited by 31
“This is a major limitation that can be resolved by traditional AAV gene replacement strategies, which have also been studied in recent years [120,121].”
BackgroundFahoum, F., & Eyal, S. (2023) · Epilepsia · doi:10.1111/epi.17625 · Cited by 30
ILAE Genetics Literacy series: Progressive myoclonus epilepsies
Cameron, J. M., Ellis, C. A., Berkovic, S. F., for the ILAE Genetics Commission, & the ILAE Genetic Literacy Task Force (2023) · Epileptic Disorders · doi:10.1002/epd2.20152 · Cited by 29
“57 This is the first disease-modifying treatment for a type of PME and holds the promise that similar approaches may be successful in other forms of PME.”
BackgroundNickel, M., & Schulz, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.785841 · Cited by 27
“These CLN2 natural history data have successfully been used as natural-history controls in a clinical trial testing safety and efficacy of intraventricular enzyme replacement therapy with cerliponase alfa (43).”
MethodSelf-citationPrecision medicine in epilepsy
McGinn, R. J., Stein, E. L. V., Stromberg, J. E. S., & Li, Y. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.04.001 · Cited by 28
An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening
Kinarivala, N., Morsy, A., Patel, R., Carmona, A. V., Sajib, M. S., Raut, S., Mikelis, C. M., Al-Ahmad, A. J., & Trippier, P. C. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00077 · Cited by 26
Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease
Kovacs, K. D., Patel, S. C., Orlin, A., Kim, K., Everen, S. A. V., Conner, T., Sondhi, D., Kaminsky, S. M., D’Amico, D. J., Crystal, R. G., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.01.011 · Cited by 27
Sanz, P., & Serratosa, J. M. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.5 · Cited by 26
“In addition, both EMA and FDA have approved the intracerebroventricular administration of enzyme replacement therapy [with cerliponase alpha, a human pro-enzyme of TPP1 (tripeptidyl peptidase 1)] for CLN2 (Refs 62, 63).”
Goldstein, A. C., & Rahman, S. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12320 · Cited by 25
“A recent example of a new drug approval using retrospective natural history data is the approval of Brineura (cerliponase alfa) for CLN2 Batten disease.(16) One of the largest prospective natural history studies was recently published, examining a cohort of 151 subjects from 61 families with the common pathogenic m.”
BackgroundNeurological glycogen storage diseases and emerging therapeutics
Colpaert, M. G., Singh, P. K., Donohue, K. J., Pires, N. T., Fuller, D. D., Corti, M., Byrne, B. J., Sun, R. C., Kooi, C. W. V., & Gentry, M. S. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00446 · Cited by 27
“Recently, FDA approved i.c.v.-based ERT therapy for a fatal CNS-centric LSD, ceroid lipofuscinosis type 2 (CLN2) [202].”
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 26
Silva, P. J., Dahlke, D. V., Smith, M. L., Charles, W., Gómez, J., Ory, M. G., & Ramos, K. S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050713 · Cited by 27
“certain degradation products, the control was disease progression in a historical standard of care cohort [60].”
BackgroundNeuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder
Ahrens‐Nicklas, R. C., Tecedor, L., Hall, A. F., Лысенко, Е., Cohen, A. S., Davidson, B. L., & Marsh, E. D. (2019) · JCI Insight · doi:10.1172/jci.insight.131961 · Cited by 28
“States as of 2018 (40), only 1, intraventricular cerliponase alfa therapy for CLN2 disease, is approved for a neurologic indication (41).”
BackgroundPrecision therapies for genetic epilepsies in 2025: Promises and pitfalls
Wang, S., Perucca, E., Berkovic, S. F., & Perucca, P. (2025) · Epilepsia Open · doi:10.1002/epi4.70065 · Cited by 25
“33 The primary endpoint (change in the composite motor-language score of the CLN2 Rating Scale) showed a markedly slower rate of functional decline in the treatment group in comparison to the historical control group ( p 0.001).”
InfluentialFrancelle, L., & Mazzulli, J. R. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147798 · Cited by 23
Sato, Y., Minami, K., Hirato, T., Tanizawa, K., Sonoda, H., & Schmidt, M. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00893-3 · Cited by 25
“Of late, ICV administration has been suggested as a viable drug delivery route to the brain parenchyma, as exemplified by the ICV administration of cerliponase alfa for the treatment of neuronal ceroid lipofuscinosis type 2 (Schulz et al. 2018; de Los Reyes et al. 2020).”
BackgroundThe neuronal ceroid-lipofuscinoses (Batten disease)
Mole, S., Schulz, A., & Haltia, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00004-7 · Cited by 23
Self-citationGlial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses
Takahashi, K., Nelvagal, H. R., Lange, J., & Cooper, J. D. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.886567 · Cited by 25
“However, ERT is only disease-modifying, and several longer-term challenges regarding whether efficacy will be maintained, the delivery systems used and potential immune responses remain (36, 37, 40).”
BackgroundMuschol, N., Koehn, A. F., von Cossel, K., Okur, İ., Ezgü, F. S., Harmatz, P., López, M. J. D. C., Couce, M. L., Lin, S., Batzios, S. P., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci165076 · Cited by 22
“Safety data for tralesinidase alfa (300 mg) administered weekly via ICV infusion are in line with other ERTs, especially those administered via ICV dosing such as cerliponase alfa (15).”
MethodApplying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses
Kline, R., Wishart, T. M., Mills, K. A., & Heywood, W. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.012 · Cited by 25
Whiting, R. E. H., Pearce, J. W., Vansteenkiste, D. P., Bibi, K. F., Lim, S., Kick, G. R., Castaner, L. J., Sinclair, J., Chandra, S. A. M., Nguyen, A., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108130 · Cited by 22
Santi, M., Finamore, F., Cecchettini, A., Santorelli, F. M., Doccini, S., Rocchiccioli, S., & Signore, G. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00615 · Cited by 23
Schwering, C., Kammler, G., Wibbeler, E., Christner, M., Knobloch, J. K. ‐., Nickel, M., Denecke, J., Baehr, M., & Schulz, A. (2021) · Journal of Child Neurology · doi:10.1177/0883073821989154 · Cited by 23
“Movement disorders are common in CLN2 patients.(2,3,16,17) Movements of facial muscles can cause mobilization of the needle in the scalp and result in needle dislodgement.”
BackgroundSelf-citationNeuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets
Ziółkowska, E., Takahashi, K., Dickson, P., Sardiello, M., Sands, M. S., & Cooper, J. D. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01132-4 · Cited by 22
“One of the largest steps forward in the treatment landscape of NCLs is the development, successful clinical testing and subsequent FDA approval of ERT for CLN2 disease 11,12,47–51 .”
InfluentialPreclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations
Kashyap, S. N., Boyle, N. R., & Roberson, E. D. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01348-6 · Cited by 22
“This treatment, called cerliponase alfa (Brineura), is a recombinant TPP1 infused biweekly via intracerebroventricular catheter and dramatically slows the progression of disease [61].”
MethodWhiting, R. E. H., Kick, G. R., Ota‐Kuroki, J., Lim, S., Castaner, L. J., Jensen, C. A., Kowal, J. B., Nguyen, A., Corado, C. R., O’neill, C. A., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108135 · Cited by 23
Inherited Metabolic Disorders Presenting with Ataxia
Silver, G., & Mercimek‐Andrews, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155519 · Cited by 21
“Recently, intracerebroventricular cerliponase alfa infusions for the treatment of CLN2 (TPP1) disease was approved for clinical use [27,30].”
BackgroundSpiezio, A. D., Marques, A. R. A., Schmidt, L., Thießen, N., Gallwitz, L., Fogh, J. M., Bartsch, U., & Säftig, P. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166205 · Cited by 26
Spaull, R., Soo, A. K. S., Hogarth, P., Hayflick, S. J., & Kurian, M. A. (2021) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.661 · Cited by 24
Silva, A., Sagné, C., Gazeau, F., & Abasolo, I. (2022) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2022.09 · Cited by 22
Cadaoas, J., Hu, H., Boyle, G., Gomero, E. M., Mosca, R., Jayashankar, K., Machado, M., Cullen, S., Guzman, B., van de Vlekkert, D., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.012 · Cited by 21
Dulz, S., Schwering, C., Wildner, J., Spartalis, C., Schuettauf, F., Bartsch, U., Wibbeler, E., Nickel, M., Spitzer, M. S., Atiskova, Y., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321260 · Cited by 20
Self-citationAl‐Saady, M. L., Beerepoot, S., Plug, B. C., Breur, M., Galabova, H., Pouwels, P. J. W., Boelens, J. J., Lindemans, C. A., van Hasselt, P. M., Matzner, U., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51796 · Cited by 21
“ERT has also been proved effective in late-infantile neuronal ceroid lipofuscinosis, a lysosomal GM disorder.(29) Proper posttranslational modification of ASA produced under bioreactor conditions might also facilitate endocytosis into neurons and glial cells, which is unlikely with macrophage-produced ASA.”
Clinical approach to neurodegenerative disorders in childhood: an updated overview
Mastrangelo, M. (2019) · Acta Neurologica Belgica · doi:10.1007/s13760-019-01160-0 · Cited by 21
“1 3 while promising results were recently obtained with cerliponase alpha for the treatment of ceroid lipofuscinosis type 2 [22, 43].”
BackgroundAtiskova, Y., Bartsch, S., Danyukova, T., Becker, E., Hagel, C., Storch, S., & Bartsch, U. (2019) · Scientific Reports · doi:10.1038/s41598-019-50726-8 · Cited by 22
Gene Therapy for Neurologic Disease: A Neurosurgical Review.
Hitti, F., Gonzalez-Alegre, P., & Lucas, T. H. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2018.09.097 · Cited by 16
Lukács, Z., Nickel, M., Murko, S., Cobos, P. N., Schulz, A., Santer, R., & Kohlschütter, A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.02.010 · Cited by 20
Self-citationMondal, A., Appu, A. P., Sadhukhan, T., Bagh, M. B., Prévide, R. M., Sadhukhan, S., Stojilković, S. S., Liu, A., & Mukherjee, A. B. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12485 · Cited by 19
“To date, enzyme- and gene-replacement have been explored in many LSDs, but the only enzyme replacement currently approved for use in the NCL family of patients is for CLN2-deficiency.(71) In our present study, we sought to explore the therapeutic potential of IP3R1-overexpression in CLN1-disease.”
BackgroundTakahashi, K., Eultgen, E. M., Wang, S. H., Rensing, N. R., Nelvagal, H. R., Dearborn, J. T., Danos, O., Buss, N. A. P. S., Sands, M. S., Wong, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165908 · Cited by 19
“Although ERT slows CLN2 disease progression (9), cerliponase alfa is not curative and requires biweekly lifelong administration.”
Ziółkowska, E., Jansen, M. J., Williams, L. L., Wang, S. H., Eultgen, E. M., Takahashi, K., Le, S. Q., Nelvagal, H. R., Sharma, J., Sardiello, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj1445 · Cited by 21
Specchio, N., Pietrafusa, N., Perucca, E., & Cross, J. H. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.107961 · Cited by 21
Self-citationWelford, R. W. D., Farine, H., Steiner, M. A., Garzotti, M., Dobrenis, K., Sievers, C., Strasser, D. S., Amraoui, Y., Groenen, P. M. A., Giugliani, R., et al. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100843 · Cited by 26
Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses
Trivisano, M., Ferretti, A., Calabrese, C., Pietrafusa, N., Piscitello, L. M., Pavia, G. C., Vigevano, F., & Specchio, N. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.845877 · Cited by 21
“Nevertheless, a targeted treatment with human recombinant enzyme is currently available only for CLN2 disease (12).”
BackgroundSelf-citationVillani, N. A., Bullock, G., Michaels, J. R., Yamato, O., O’Brien, D. P., Mhlanga-Mutangadura, T., Johnson, G. S., & Katz, M. L. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.04.003 · Cited by 21
“Indeed, an enzyme replacement therapy for treating CLN2 disease that was successful in delaying disease onset and slowing the progression of clinical signs in a dog model is now being used successfully to treat children with this disorder [33-37].”
BackgroundGlobal Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model
Domowicz, M. S., Chan, W., Vázquez, P. N. C., Henry, J. G., Ware, C. B., Andrade, J., Dawson, G., & Schwartz, N. B. (2019) · ASN NEURO · doi:10.1177/1759091419843393 · Cited by 21
“This treatment appears to reduce the loss of walking ability in human trials (clinical trial NCT01907087), but it is expensive and may lead to many side effects due to the prolonged nature of the treatment (Schulz et al., 2018).”
BackgroundTreatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features
Galosi, S., Nardecchia, F., & Leuzzi, V. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12897 · Cited by 22
“The recently demonstrated efficacy of intraventricular cerliponase alfa in delaying or plateauing the progression of the disease makes a timely diagnosis of the disease now important, whatever the phenotypic presentation.(60)”
BackgroundWhite, K. A., Nelvagal, H. R., Poole, T. A., Lü, B., Johnson, T. B., Davis, S. S., Pratt, M. A., Brudvig, J. J., Assis, A. B., Likhite, S. B., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.014 · Cited by 20
The neuronal ceroid-lipofuscinoses (Batten disease)
Mole, S., & Schulz, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00018-2 · Cited by 19
Self-citationBerg, A. T., Kaat, A. J., & Gaebler-Spira, D. J. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108953 · Cited by 18
External control arms for rare diseases: building a body of supporting evidence
Khachatryan, A., Read, S. H., & Madison, T. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09858-8 · Cited by 18
“This drug was approved in 2017 by the FDA and EMA on the basis of comparisons between the primary outcomes of 23 treated patients participating in a phase 1/2 open-label single arm trial and 42 historical controls derived from the DEM-CHILD database, a European registry [ 19 ].”
MethodEmerging trends in virus and virus-like particle gene therapy delivery to the brain
Mandalawatta, H. P. P., Rajendra, K. C., Fairfax, K. A., & Hewitt, A. W. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102280 · Cited by 22
“192 However, these invasive delivery techniques have an inherent risk of surgery-related side effects, and, therefore, alternative, less invasive delivery strategies are required.”
BackgroundLysosomal storage disorders: pathology within the lysosome and beyond
Kielian, T. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14672 · Cited by 21
“…the mechanism by which enzyme replacement therapy is successful, by delivering M6P-tagged enzymes that are mutated in select LSDs (i.e., neuronal ceroid lipofuscinosis type 2 disease, Fabry disease, and Pompe disease) to lysosomes (Schiffmann et al. 2000; Thurberg et al. 2006; Schulz et al. 2018).”
Emerging treatments for progressive myoclonus epilepsies
Riva, A., Guglielmo, A., Balagura, G., Marchese, F., Amadori, E., Iacomino, M., Minassian, B. A., Zara, F., & Striano, P. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1741350 · Cited by 19
“Further studies will subscribe its efficacy in preventing the onset of symptoms in early-treated patients [63,64].”
BackgroundSeifu, Y., Gamalo, M., Barthel, F. M.-S., Lin, J., Qiu, J., Cooner, F., Ruan, S., & Walley, R. J. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00170-y · Cited by 18
Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses
Iwan, K., Clayton, R., Mills, P. B., Csányi, B., Gissen, P., Mole, S., Palmer, D. N., Mills, K. A., & Heywood, W. (2020) · iScience · doi:10.1016/j.isci.2020.102020 · Cited by 20
Self-citationMazurkiewicz‐Bełdzińska, M., del Toro, M., Haliloğlu, G., Huidekoper, H. H., Kravljanac, R., Mühlhausen, C., Andersen, B. N., Prpić, I., Striano, P., & Auvin, S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1885374 · Cited by 18
“symptomatic children aged ≥3 years in the USA) following trials showing that intracerebroventricular infusions every other week reduce the rate of decline of motor and language function [37].”
BackgroundAn ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy
Thompson, D., Handley, S. E., Henderson, R., Marmoy, O. R., & Gissen, P. (2021) · Eye · doi:10.1038/s41433-021-01594-y · Cited by 18
“It is being used to monitor disease trajectory in the intraventricular Cerliponase Alfa study [17].”
MethodSelf-citationDoccini, S., Marchese, M., Morani, F., Gammaldi, N., Mero, S., Pezzini, F., Soliymani, R., Santi, M., Signore, G., Ogi, A., et al. (2022) · Cells · doi:10.3390/cells11111840 · Cited by 19
“is currently available for most forms of NCL but CLN2, in which an enzymatic replacement therapy has been demonstrated to modify the disease trajectories if started early in the course of a disease [2,3].”
BackgroundWibbeler, E., Wang, R., Reyes, E. D. L., Specchio, N., Gissen, P., Guelbert, N. B., Nickel, M., Schwering, C., Lehwald, L. M., Trivisano, M., et al. (2020) · Journal of Child Neurology · doi:10.1177/0883073820977997 · Cited by 18
Self-citationJin, Y., Zhang, Y., Song, M., Zhou, J., Zhang, H., & Ding, Y. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100344 · Cited by 24
Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep
Nelvagal, H. R., Eaton, S. L., Wang, S. H., Eultgen, E. M., Takahashi, K., Le, S. Q., Nesbitt, R., Dearborn, J. T., Siano, N., Puhl, A. C., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163107 · Cited by 18
Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa
Schulz, A., Schwering, C., Wibbeler, E., Westermann, L. M., Hagenah, L., Lezius, S., Jha, A., Hunt, A., Slasor, P., Reisewitz, P., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1516026 · Cited by 17
Self-citationNeuronal ceroid lipofuscinosis: genetic and phenotypic spectrum of 14 patients from Turkey
Köse, M., Köse, E., Ünalp, A., Yılmaz, Ü., Edizer, S., Tekin, H. G., Karaoğlu, P., Özdemir, T. R., Er, E., Önay, H., et al. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05067-8 · Cited by 17
Gissen, P., Specchio, N., Olaye, A., Jain, M. M., Butt, T., Ghosh, W., Ruban‐Fell, B., Griffiths, A., Camp, C., Sisic, Z., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01829-x · Cited by 17
“The relative improvement in HRQoL, as indicated by the difference in utility values of treated and untreated patients, is consistent with observed clinical outcomes; in patients treated with cerliponase alfa for up to 141 weeks, it was observed that there was a significant attenuation in the rate of decline in CLN2 Cl…”
MethodResultSelf-citationClinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies
Brock, D. C., Demarest, S., & Benke, T. A. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01123-5 · Cited by 18
“1 3 refractory epilepsy following symptom onset, had no targeted therapy or DMT prior to the approval of cerliponase alfa in 2018 [53].”
BackgroundInfluentialHeller, G., Bradbury, A. M., Sands, M. S., & Bongarzone, E. R. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.017 · Cited by 23
“136,137,147 Implantable CNS injection devices have existed for some time, but using them for ERT has been limited due to the frequent injections, as often as every 2 weeks, and long injection time required for ERT.”
Kim, A., Grover, A., Hammon, K., de Hart, G., Slasor, P., Cherukuri, A., Ajayi, T., Jacoby, D. R., Schulz, A., Specchio, N., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12925 · Cited by 16
Self-citationClinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group
Sampaio, L. P. D. B., de Manreza, M. L. G., Pessoa, A. L. S., Gurgel‐Giannetti, J., Coan, A. C., van der Linden, H., Embiruçu, E. K., Henriques‐Souza, A. M. D. M., & Kok, F. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1761434 · Cited by 16
Liu, J., Bassal, M., Schlichting, S., Braren, I., Spiezio, A. D., Säftig, P., & Bartsch, U. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105628 · Cited by 16
Yue, W., & Shen, J. (2023) · Pharmaceuticals · doi:10.3390/ph16060810 · Cited by 17
“For example, a grade 3 infection, leakage, and an increased count of white cells in the CSF were previously reported in patients [17].”
BackgroundPharmacodynamic rationale for the choice of antiseizure medications in the paediatric population
D’Onofrio, G., Roberti, R., Riva, A., Russo, E., Verrotti, A., Striano, P., & Belcastro, V. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00344 · Cited by 18
Speech, Language and Non‐verbal Communication in CLN2 and CLN3 Batten Disease
Morison, L. D., Whiteman, I. T., Vogel, A. P., Tilbrook, L., Fahey, M. C., Braden, R. O., Bredebusch, J., Hildebrand, M. S., Scheffer, I. E., & Morgan, A. T. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12838 · Cited by 16
“The development of precision medicine for CLN2 disease has been transformational, with enzyme replacement therapy (ERT) slowing disease progression [16–18].”
The concept of disease modification
Cross, J. H., & Lagae, L. G. (2019) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.12.005 · Cited by 15
Nelvagal, H. R., Hurtado, M. L., Eaton, S. L., Kline, R., Lamont, D. J., Sands, M. S., Wishart, T. M., & Cooper, J. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-72075-7 · Cited by 15
On the cusp of cures: Breakthroughs in Batten disease research
Brudvig, J. J., & Weimer, J. M. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.08.003 · Cited by 15
Hochstein, J.-N., Schulz, A., Nickel, M., Lezius, S., Grosser, M., Fiehler, J., Sedlacik, J., & Löbel, U. (2022) · Neuroradiology · doi:10.1007/s00234-022-02988-9 · Cited by 18
Self-citationNeuronal Ceroid Lipofuscinoses in Children
Kamate, M., Reddy, N., Detroja, M., & Hattiholi, V. V. (2021) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_61_20 · Cited by 15
Gait phenotype in Batten disease: A marker of disease progression
Østergaard, J. R. (2021) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2021.09.004 · Cited by 17
Howell, K. B., White, S. M., McTague, A., D’Gama, A. M., Costain, G., Poduri, A., Scheffer, I. E., Chau, V., Smith, L., Stephenson, S. E. M., et al. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00474-8 · Cited by 18
“Such ‘ historical control ’ data have been integral to demonstrating the bene fi t of novel treatments for spinal muscular atrophy and neuronal ceroid lipofuscinosis type 2 disease 83,84 .”
Sugiman‐Marangos, S. N., Beilhartz, G. L., Zhao, X., Zhou, D., Hua, R., Kim, P. K., Rini, J. M., Minassian, B. A., & Melnyk, R. A. (2020) · Science Advances · doi:10.1126/sciadv.abb0385 · Cited by 14
“6 of 8 While the ability of LTM-TPP1 to affect disease progression has yet to be determined, recent positive clinical trial results (35) and the subsequent approval of rTPP1 (cerliponase alfa) for treatment of neuronal ceroid lipofuscinosis 2 (NCL2) provide support for this approach.”
BackgroundLeal‐Pardinas, F., Truty, R., McKnight, D., Johnson, B. A., Morales, A., Bristow, S. L., Pang, T. Y., Cohen-Pfeffer, J. L., Izzo, E., Sankar, R., et al. (2022) · Epilepsia · doi:10.1111/epi.17269 · Cited by 14
Manti, F., Mastrangelo, M., Battini, R., Carducci, C., Spagnoli, C., Fusco, C., Tolve, M., Carducci, C., & Leuzzi, V. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.08.033 · Cited by 14
New Therapeutic Approaches to Inherited Metabolic Pediatric Epilepsies
Pearl, P. L., Latzer, I. T., Lee, H. H. C., & Rotenberg, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207133 · Cited by 14
Batten disease: an expert update on agents in preclinical and clinical trials
Masten, M. C., Mink, J. W., & Augustine, E. F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1837110 · Cited by 14
Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
Nickel, M., Gissen, P., Greenaway, R., Cappelletti, S., Hamborg, C., Ragni, B., Ribitzki, T., Schulz, A., Tondo, I., & Specchio, N. (2023) · Neuropediatrics · doi:10.1055/s-0043-1770143 · Cited by 13
“10,11 The availability of treatment that can potentially prolong the quality and quantity of life demands an immediate increase in the awareness of CLN2 disease among health care professionals (HCPs).”
BackgroundSelf-citation
Metadata
- Authors
- Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J. P., Cahan, H., Slasor, P., Jacoby, D., & Kohlschütter, A.
- Affiliations
- Nationwide Children's Hospital (US)
- From the Department of Pediatrics, University Medical Center Hamburg–Eppendorf, Hamburg, Germany (A.S., A.K.); BioMarin Pharmaceutical, Novato, CA (T.A., H.C., P.S., D.J.); the Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome (N.S.); Nationwide Children’s Hospital and Ohio State University, Columbus (E.L.R.); UCL Great Ormond Street Institute of Child Health, London (P.G.); and the Citigroup Biomedical Imaging Center, Departments of Radiology and Genetic Medicine, Weill...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1898-1907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2799850385
- Cited by
- 489
- References
- 17
- Citations by year
- 2026: 36 · 2025: 57 · 2024: 37 · 2023: 49 · 2022: 86 · 2021: 74 · 2020: 83 · 2019: 47 · 2018: 17
- FWCI
- 37.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health Research
- European Union Seventh Framework Program Grand (281234)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- cerliponase alfa, CLN2 disease, neuronal ceroid lipofuscinosis type 2, intraventricular infusion, enzyme replacement therapy, tripeptidyl peptidase 1, lysosomal storage disease, pediatric patients, device-related infection, adverse events
- MeSH terms
- Tripeptidyl-Peptidase 1, Adolescent, Child, Child, Preschool, Dementia, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Female, Humans, Language Development, Male, Motor Skills, Neuronal Ceroid-Lipofuscinoses, Recombinant Proteins, Disease Progression, Kaplan-Meier Estimate, Enzyme Replacement Therapy, Infusions, Intraventricular, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.